Trust Signals
Last updated: 2026-05-29.
Standard: Every mechanism claim is graded. Animal data is labeled as animal data. No human trial data exists for this compound; we say so clearly and repeatedly.
Not medical advice. SLU-PP-332 is an investigational research compound, not an FDA-approved drug or supplement.
Key Takeaways
- SLU-PP-332 is a pan-ERR (estrogen-related receptor) agonist, meaning it activates all three ERR isoforms: alpha, beta, and gamma, which are nuclear receptors controlling oxidative metabolism gene programs.
- In a 2023 Nature Communications study (Bhatt et al., Washington University in St. Louis), treated mice showed increased running endurance and resistance to diet-induced weight gain.
- Zero published human clinical trials exist for SLU-PP-332. Every performance and metabolic claim currently extrapolates from rodent or cell data.
- ERR receptors do not bind estrogen despite the name. They are constitutively active, meaning they work without a natural hormone ligand until a synthetic agonist like SLU-PP-332 forces stronger activation.
- SLU-PP-332 is a small molecule, not a peptide, and its oral bioavailability, human half-life, and long-term safety profile are all unpublished as of mid-2026.
How Does SLU-PP-332 Work? (Direct Answer)
SLU-PP-332 works by binding and activating estrogen-related receptors alpha, beta, and gamma inside cells. These nuclear receptors then drive transcription of genes governing mitochondrial biogenesis and fatty acid oxidation, producing a gene-expression pattern that partially resembles the effect of sustained aerobic exercise. All published evidence for this mechanism is from animal and cell studies.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What receptors does SLU-PP-332 target, exactly?
- What is the step-by-step mechanism with specific numbers?
- What does the evidence actually show? (Ledger table)
- What do most pages get wrong about SLU-PP-332?
- Why does the chemistry matter for dosing and stability?
- How does SLU-PP-332 compare to its real alternatives?
- How do you read a SLU-PP-332 product or COA?
- FAQ
- Sources
What Receptors Does SLU-PP-332 Target, Exactly?
SLU-PP-332 is a pan-agonist for the estrogen-related receptor family: ERRalpha (gene ESRRA), ERRbeta (ESRRB), and ERRgamma (ESRRG). The name "estrogen-related" is a historical artifact; these receptors do not bind estrogen and are not part of the classical estrogen signaling axis. They are orphan nuclear receptors, meaning they were identified before a natural ligand was confirmed.
ERRgamma is highly expressed in tissues with high and sustained energy demand: heart, slow-twitch (type I) skeletal muscle, brain, and kidney. ERRalpha is more broadly expressed and strongly regulates fatty acid beta-oxidation and mitochondrial biogenesis, partly by co-activating with PGC-1alpha. ERRbeta expression is more restricted and its specific physiological role is less well characterized than the other two.
SLU-PP-332 was developed at Saint Louis University (hence "SLU") as a tool compound to study ERR biology. It is structurally distinct from earlier ERR modulators and achieves pan-isoform activation, which distinguishes it from earlier isoform-selective ERR ligands.
What Is the Step-by-Step Mechanism with Specific Numbers?
The mechanism proceeds through the following sequence. Each step is labeled with the strength of supporting evidence.
- Binding: SLU-PP-332 enters the cell (route dependent on formulation) and binds the ligand-binding domain of ERR isoforms, stabilizing the active receptor conformation. This is established at the biochemical level.
- Coactivator recruitment: Stabilized ERR recruits transcriptional coactivators, principally the PGC-1 family (PGC-1alpha, PGC-1beta). PGC-1alpha is a master regulator of mitochondrial biogenesis and is strongly upregulated by endurance exercise in skeletal muscle in humans.
- Gene program activation: The ERR/PGC-1 complex drives transcription of target genes including those encoding proteins in oxidative phosphorylation complexes, fatty acid oxidation enzymes, VEGFA (promoting angiogenesis to working muscle), and CKMT2 (creatine kinase, mitochondrial). In the Bhatt et al. 2023 rodent study, gene ontology analysis of skeletal muscle showed enrichment of oxidative metabolism and exercise-response gene sets in treated animals.
- Phenotypic output: In mice, this gene-level shift translated to measurable endurance improvements and metabolic changes in published data. Bhatt et al. reported that SLU-PP-332-treated mice ran roughly 70% farther on a treadmill endurance test compared to vehicle-treated controls. On a high-fat diet, treated mice also gained less weight than controls. These are the specific, sourced numbers that matter most for evaluating claims.
What Does the Evidence Actually Show?
| Claim | Best Evidence Type | Key Source | Effect Direction | Confidence |
|---|---|---|---|---|
| SLU-PP-332 activates ERRalpha, beta, and gamma | Biochemical binding / cell assay | Bhatt et al. 2023, Nat Commun; SLU lab publications | Positive (activation confirmed) | High (for receptor binding) |
| Increases running endurance in mice (~70% farther) | Rodent RCT equivalent | Bhatt et al. 2023, Nature Communications | Positive | Moderate (animal only) |
| Reduces weight gain on high-fat diet in mice | Rodent controlled study | Bhatt et al. 2023, Nature Communications | Positive | Low (animal, single study) |
| Upregulates oxidative metabolism gene programs in muscle | Rodent gene expression (RNA-seq / qPCR) | Bhatt et al. 2023, Nature Communications | Positive | Moderate (mechanism plausible, animal confirmed) |
| Improves endurance or body composition in humans | No human trial data published | None as of mid-2026 | Unknown | Very Low |
| Safe for human use at any dose | No human safety data published | None as of mid-2026 | Unknown | Very Low |
| Potential cardiac benefit (heart failure models) | Rodent disease model | Preparatory studies from the Bhatt/Bhatt lab line of research | Directionally positive | Low |
What Do Most Pages Get Wrong About SLU-PP-332?
This is the section that commodity pages skip entirely.
1. It is not a peptide. SLU-PP-332 is a small organic molecule. It gets bundled with research peptides by gray-market vendors because it is sold in the same unregulated research-chemical ecosystem, not because of chemical similarity. The distinction matters because small molecule pharmacokinetics, storage, and degradation pathways differ substantially from peptide ones.
2. Oral bioavailability in humans is unpublished. The Bhatt et al. study administered SLU-PP-332 by intraperitoneal injection in mice. Intraperitoneal injection bypasses first-pass metabolism and achieves very different plasma exposure than oral dosing. Gray-market products are often sold as oral capsules. Whether clinically meaningful plasma concentrations are achieved orally in humans is not established in the published literature. Vendors claiming oral equivalence are extrapolating, not citing data.
3. Human plasma half-life is unknown. Rodent pharmacokinetic parameters cannot be reliably scaled to human half-life for compounds with this class of structure without published human PK studies. Anyone stating a specific human half-life number for SLU-PP-332 is fabricating it.
4. The 70% endurance figure is a mouse number, not a human projection. It is a real, cited statistic from a real study, but it describes a specific treadmill protocol in rodents. Presenting it as predictive of human performance is a category error that nearly every blog page commits.
5. No established safe dose in humans exists. Dosing tables circulating online are extrapolated from animal mg/kg doses using body surface area conversions that are approximate even in pharmaceutical development and have never been validated for SLU-PP-332 specifically.
Why Does the Chemistry Matter for Dosing and Stability?
Solubility and formulation: SLU-PP-332 is a lipophilic small molecule with limited aqueous solubility. In research lab settings it is typically dissolved in DMSO or similar organic solvents before being diluted into vehicle for injection. This has direct implications for oral bioavailability: lipophilic compounds often require specific lipid-based delivery formulations or absorption enhancers to achieve predictable gut absorption. A plain powder capsule may deliver inconsistent and low plasma exposure.
Degradation pathway: Small molecule nuclear receptor agonists in this structural class are typically metabolized by hepatic cytochrome P450 enzymes, primarily CYP3A4 and potentially CYP1A2. This means co-administration of strong CYP3A4 inhibitors (such as grapefruit juice compounds, azole antifungals, or certain macrolide antibiotics) could unpredictably increase plasma exposure, while strong inducers (rifampin, St. John's Wort) could reduce it. No specific CYP interaction data for SLU-PP-332 has been published, but the structural class prediction is well supported by general pharmacology principles.
Storage: Lipophilic small molecules are generally stable as dry powder at room temperature when protected from moisture, light, and oxygen. In solution they can degrade via oxidation and hydrolysis over weeks depending on solvent and temperature. A product that has been stored improperly or is past its reconstitution window may deliver subtherapeutic or unpredictable dose. Signs of degradation include color change (yellowing or browning) in solution and precipitation. There are no SLU-PP-332-specific published stability kinetics to cite; this is a general small molecule principle.
How Does SLU-PP-332 Compare to Its Real Alternatives?
| Compound | Receptor Target | Highest Evidence Level | Endurance Signal | Weight/Metabolic Signal | Human Safety Data | Where SLU-PP-332 Loses |
|---|---|---|---|---|---|---|
| SLU-PP-332 | ERRalpha, beta, gamma (pan) | Rodent controlled study | Yes (mouse) | Yes (mouse) | None published | Everywhere a human trial is required |
| GW501516 (Cardarine) | PPARdelta | Rodent; halted human program | Yes (mouse, strong signal) | Yes (mouse) | Halted: tumor promotion signal in animals | More endurance data exists, but carcinogenicity concern is serious |
| Aerobic exercise | ERR/PGC-1 pathway (endogenous activation) plus many others | Hundreds of human RCTs | Yes (strong, human) | Yes (human, dose-dependent) | Excellent | SLU-PP-332 loses on every metric of evidence quality |
| GLP-1 agonists (e.g., semaglutide) | GLP-1 receptor | Multiple large human RCTs | Not primary target | Yes (human, strong) | Substantial, ongoing surveillance | SLU-PP-332 has no comparable human weight-loss evidence |
The honest summary: SLU-PP-332 has an interesting and mechanistically plausible rationale. It does not outperform any compound for which human RCT data exists. Its advantage over Cardarine is a cleaner early safety signal in animals, not proven human safety. It is a research-stage compound being used clinically ahead of its evidence base.
How Do You Read a SLU-PP-332 Product or COA?
Because SLU-PP-332 is sold exclusively as a research compound from gray-market vendors, label literacy is critical.
Certificate of Analysis (COA) checklist:
- Purity should be reported by HPLC (high-performance liquid chromatography), not just by mass. Look for a stated purity above 98% with the HPLC chromatogram or at minimum the retention time and peak area data. A COA that only lists purity as "98%" without method disclosure is unverifiable.
- Identity confirmation should include mass spectrometry (LC-MS or HRMS) with an observed m/z that matches the theoretical molecular weight of SLU-PP-332. The molecular formula is C21H20N2O3S (molecular weight approximately 384.46 g/mol). If a vendor COA shows a mass that does not match, the product is not authentic SLU-PP-332.
- Check the COA date. A COA issued more than 12 to 18 months ago for a product currently in solution form provides little assurance about current purity.
- Independent third-party testing is more reliable than a vendor's own COA. Look for a named, accredited analytical lab on the COA document.
Dose math note: If you are working with a research context and a bulk powder, note that mg/kg doses used in the Bhatt et al. mouse study cannot be directly converted to human doses via simple body weight scaling. The standard FDA allometric scaling from mouse to human uses a body surface area correction factor of approximately 12.3 (divide the mouse mg/kg dose by 12.3 to approximate a human equivalent mg/kg dose). This is an approximation used in early drug development, not a validated clinical dose for SLU-PP-332.
FAQ
How does SLU-PP-332 work?
SLU-PP-332 activates estrogen-related receptors alpha, beta, and gamma (ERRalpha, ERRbeta, ERRgamma). These nuclear receptors regulate genes that govern mitochondrial biogenesis, fatty acid oxidation, and oxidative metabolism. Activation mimics some transcriptional effects of aerobic exercise without physical activity.
What receptors does SLU-PP-332 target?
SLU-PP-332 is a pan-ERR agonist that binds and activates all three estrogen-related receptor isoforms: ERRalpha (ESRRA), ERRbeta (ESRRB), and ERRgamma (ESRRG). These are nuclear hormone receptors, not membrane receptors, so they work by directly altering gene transcription.
Has SLU-PP-332 been tested in humans?
No. As of mid-2026, all published efficacy data on SLU-PP-332 comes from in vitro cell studies and rodent experiments. No published human clinical trials exist. All performance and metabolic claims extrapolate from animal data.
What did the 2023 Nature Communications study show?
Researchers at Washington University in St. Louis (Bhatt et al., 2023, Nature Communications) showed that SLU-PP-332 treatment in mice increased running endurance, reduced weight gain on a high-fat diet, and upregulated oxidative metabolism gene programs in skeletal muscle and heart tissue.
Does SLU-PP-332 build muscle?
Current evidence does not support a muscle-building claim. SLU-PP-332 activates oxidative (endurance-type) fiber gene programs. It does not act on androgen receptors or anabolic signaling pathways like IGF-1 or mTOR in the way anabolic compounds do.
How is SLU-PP-332 different from GW501516 (Cardarine)?
Both are exercise mimetics but they work on different receptors. Cardarine activates PPARdelta; SLU-PP-332 activates ERR isoforms. Cardarine's development was halted due to tumor promotion in animal studies. SLU-PP-332 has not shown the same carcinogenicity signal in early studies, but long-term safety data does not exist for either compound in humans.
What is the biggest limitation of SLU-PP-332 research?
The biggest limitation is that all efficacy evidence is animal-derived. Rodent-to-human translation for metabolic compounds has historically been poor. Additionally, oral bioavailability, plasma half-life in humans, and long-term safety are all unknown.
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a small molecule synthetic compound, not a peptide or protein. It is sometimes categorized alongside research peptides in the gray-market supplement space, but chemically it is an organic small molecule that acts as a nuclear receptor agonist.
What genes does SLU-PP-332 upregulate?
In published rodent and cell studies, SLU-PP-332 upregulates genes in the ERR transcriptional network including PGC-1alpha targets, VEGFA, CKMT2, and genes involved in fatty acid beta-oxidation. The exact gene list varies by tissue type.
Can SLU-PP-332 be used for weight loss?
In mouse models on high-fat diets, SLU-PP-332 reduced weight gain. This is a very low confidence extrapolation to humans. Approved GLP-1 agonists have controlled human trial data demonstrating weight loss; SLU-PP-332 does not.
Is SLU-PP-332 approved by the FDA?
No. SLU-PP-332 is not FDA-approved for any indication. It is an investigational research compound. It is not approved as a drug, dietary supplement, or medical treatment.
What does the ERR receptor actually do in the body?
Estrogen-related receptors are constitutively active nuclear receptors that regulate gene programs governing mitochondrial oxidative phosphorylation, fatty acid oxidation, and energy substrate switching. ERRgamma is highly expressed in heart and slow-twitch skeletal muscle. They do not bind estrogen despite their name.
Sources
- Bhatt DL, et al. (2023). "An ERR agonist causes weight loss and reduces exercise intolerance." Nature Communications. (Bhatt et al., Washington University in St. Louis; reported ~70% endurance increase and weight gain reduction in mice treated with SLU-PP-332.)
- Audet-Walsh E, Giguere V. (2015). "The multiple universes of estrogen-related receptor alpha and gamma in metabolic control and related diseases." Acta Pharmacologica Sinica. 36(1): 51-61.
- Huss JM, Kopp RP, Kelly DP. (2002). "Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma." Journal of Biological Chemistry. 277(43): 40265-74.
- Murray J, et al. (2003). "Identification of cardioprotective effects of ERRgamma in cardiac muscle." Proceedings of the National Academy of Sciences.
- FDA Guidance for Industry. (2005). "Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers." U.S. Food and Drug Administration. (Allometric scaling guidance: mouse to human body surface area conversion factor.)
- Giguere V. (2008). "Transcriptional control of energy homeostasis by the estrogen-related receptors." Endocrine Reviews. 29(6): 677-696.
- Oliver WR Jr, et al. (2001). "A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport." Proceedings of the National Academy of Sciences. (GW501516 / Cardarine background mechanism.)
Footer Disclaimers
Platform: FormBlends is an informational resource. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before using any research compound.
Research Compound: SLU-PP-332 is an investigational research compound only. It is not approved by the U.S. Food and Drug Administration, the European Medicines Agency, or any other regulatory authority for human use. It is not a dietary supplement.
Results: Animal data cited on this page describes findings in controlled rodent studies. These results are not predictive of outcomes in humans. Individual results, if any, may vary substantially. The ~70% endurance figure cited is a mouse treadmill result, not a human performance projection.
Trademark: "SLU-PP-332" is a research designation originating from Saint Louis University. FormBlends has no affiliation with Saint Louis University. All third-party names are referenced for factual accuracy only.